HORMONE REPLACEMENT IN MENOPAUSAL WOMEN

更年期女性的激素替代

• 批准号: 3789801
• 负责人: S M HARMAN
• 金额: --
• 依托单位: NATIONAL INSTITUTE ON AGING
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3789801
• 关键词: aging; binding proteins; body composition; combination chemotherapy; drug administration routes; drug adverse effect; endocrine pharmacology; estrogens; female; growth hormone releasing hormone; hormone regulation /control mechanism; hormone therapy; human old age (65+); human subject; human therapy evaluation; insulinlike growth factor; oral administration; postmenopause; progestins; secretion; somatotropin

In a group of healthy postmenopausal women whose body fat distribution and body fat mass independently range from lower (gynoid) to upper (android) distribution and from lower (lean) to higher (obese) percent fat we have found a trend to greater percent body fat with increasing age despite the absence of a significant relationship between age and body mass index. Data also suggest that dual energy x-ray absorptiometry yields estimates of body composition comparable to those obtained by hydrodensitometry. There were independent inverse correlations of waist to hip ratio (p<0.03), but not of age of body mass index, with 12 hour pulsatile GH levels and GHRH- stimulated GH peaks. These findings suggest an age-independent decrease in GH secretion attributable to android habitus in postmenopausal women. Oral estrogen treatment, produced a trend to increased spontaneous GH levels, which was significant only for the area under the peaks. Transdermal estrogens tended to decrease mean GH peak amplitude, and to increase 12 h mean GH. Oral, but not transdermal, estrogens significantly decreased basal and stimulated IGF-I, while transdermal estrogens had a greater effect on reducing IGF Binding Protein-3 than did oral estrogens. In another ongoing study of healthy women age 65-75 y treated with constant combined oral estrogen with and without low dose daily progestin, minor breast tenderness has been the only adverse effect reported to date. Four women receiving estrogen-progestin co-therapy experienced vaginal bleeding within the first three months of study requiring an increase in progestin dose.

在一组健康的绝经后妇女中，她们的体脂分布和 身体脂肪质量独立地从下部(女性)到上部(机器人) 分布以及从低(瘦)到高(肥胖)的脂肪百分比 发现随着年龄的增长，体脂比例有增加的趋势，尽管 年龄和体重指数之间没有显著的关系。 数据还表明，双能x射线吸收测量法估计 身体成分与水密度测定法获得的身体成分相当。那里 是腰臀比的独立负相关(p&lt；0.03)，但是 不是体重指数的年龄，有12小时的GH水平和GHRH- 受刺激的生长激素峰值。这些发现表明，与年龄无关的 绝经后妇女的GH分泌与Android习性有关。口头的 雌激素治疗，导致自发生长激素水平上升的趋势， 这只对山峰下的区域有意义。透皮透皮 雌激素使平均生长激素峰值降低，12h升高 卑鄙的生长激素。口服但不是经皮吸收的雌激素显著减少 基础和刺激的IGF-I，而经皮雌激素有更大的 降低胰岛素样生长因子结合蛋白-3的效果优于口服雌激素。在……里面 另一项正在进行的关于65-75岁健康女性的研究 联合口服雌激素加和不加小剂量每日孕激素，小剂量 到目前为止，乳房压痛是唯一报道的不良反应。四 接受雌激素和孕激素联合治疗的女性出现阴道出血 在需要增加孕激素的研究的前三个月内 剂量。